Created in SKOLKOVO a cure for hepatitis D has received the status of “breakthrough therapy” in the United States On the Russian market this drug will appear at the end of 2019. Upstairs MOSCOW, December 17. /TASS/. The world’s first drug from a previously incurable hepatitis D is created by a resident of the “SKOLKOVO” biotech company Hepatera, received the status of “breakthrough therapy” from control by the food and drug administration USA (US Food and Drug Administration, FDA). On Monday reported the press service of the Fund. “The drug Myrcludex B created by a resident of the SKOLKOVO Foundation, a biotech company Hepatera, received the status of “breakthrough therapy” from control by the food and drug administration USA (US Food and Drug Administration, FDA). Myrcludex B the first in the world drug cure previously incurable hepatitis D. It is also effective for the treatment of hepatitis B”, — stated
